A study focusing on immortalized human bronchial epithelial cells reported differences in the degree of constitutive activation of the KRAS protein, rates of increase in tumor cell proliferation, and the degree of activation of proliferative signals downstream of KRAS, depending on the mutation sites in the KRAS gene [14]. The gene discussed is KRAS; the disease is neoplasm.